Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Late Stent Thrombosis Following Platelet Transfusion in a Patient With Aplastic Anemia

  • Shin, Hyun-Sung (Division of Cardiovascular Medicine, Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kang, Tae-Soo (Division of Cardiovascular Medicine, Department of Internal Medicine, Dankook University College of Medicine)
  • Published : 2012.01.31
⟨ Previous Next ⟩

Abstract

Aplastic anemia is a condition in which the bone marrow fails to produce adequate numbers of peripheral blood elements. The incidences of atherosclerosis and myocardial infarction in patients with congenital coagulation disorders and chronic thrombocytopenia are very low. In this paper, a case of late stent thrombosis within a drug-eluting stent occurring after platelet transfusion in a patient with aplastic anemia is presented. The authors' observations emphasize the risks of platelet transfusion and the authors' support withholding such a treatment unless vitally indicated, in patients with coronary artery stent implantation and even in those on dual antiplatelet therapy.

Keywords

References

  1. Toyama M, Watanabe S, Kobayashi T, et al. Two cases of acute myocardial infarction associated with aplastic anemia during treatment with anabolic steroids. Jpn Heart J 1994;35:369-73. https://doi.org/10.1536/ihj.35.369
  2. Fisher M, Appleby M, Rittoo D, Cotter L. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract 1996;50:222-3.
  3. Andrade J, Al Ali A, Saw J, Wong GC. Acute stent thrombosis in a patient with giant cell arteritis. Can J Cardiol 2008;24:e25-6. https://doi.org/10.1016/S0828-282X(08)70186-7
  4. Sabovic M, Zorman SK. Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. Heart Vessels 2003;18:47-9. https://doi.org/10.1007/s003800300008
  5. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993;70:138-43.
  6. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationship between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990;63:82-6.
  7. Cornet AD, Klein LJ, Groeneveld AB. Coronary stent occlusion after platelet transfusion: a case series. J Invasive Cardiol 2007;19:E297-9.
  8. Mendez TC, Diaz O, Enriquez L, Baz JA, Fernandez F, Goicolea J. Severe thrombocytopenia refractory to platelet transfusions, secondary to abciximab readministration, in a patient previously diagnosed with idiopathic thrombocytopenic purpura: a possible etiopathogenic link. Rev Esp Cardiol 2004;57:789-91. https://doi.org/10.1016/S0300-8932(04)77192-4
  9. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002;22:1638-41. https://doi.org/10.1592/phco.22.17.1638.34125
  10. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000;65:177-8. https://doi.org/10.1002/1096-8652(200010)65:2<177::AID-AJH17>3.0.CO;2-K
  11. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S9-56. https://doi.org/10.1016/j.tmrv.2007.01.001

Cited by

  1. An unusual cause of intraoperative airway obstruction in a child with Wiskott‐Aldrich syndrome vol.2, pp.1, 2012, https://doi.org/10.21466/ac.aucoiao.2014
  2. Acute Coronary Syndromes in Patients with Hematological Disorders vol.2, pp.4, 2012, https://doi.org/10.1515/jce-2016-0024
  3. Prophylactic Preprocedure Platelet Transfusion Is Associated With Increased Risk of Thrombosis and Mortality vol.149, pp.1, 2012, https://doi.org/10.1093/ajcp/aqx151
  4. Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data vol.59, pp.suppl2, 2012, https://doi.org/10.1111/trf.15163